IMU Biosciences is coupling deep, systems-level immune profiling with a proprietary AI platform to build a uniquely detailed immune atlas spanning the breadth of human health and disease
IMU Biosciences has raised €59M across 2 funding rounds from 2 investors, most recently a round in Jun 2026. Based in London, UK; active in Healthtech. Data as of 6 Aug 2026.
Timing: too soon vs cohort gap · momentum up. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors |
|---|
| 2026-06-02 | Other | €45M | IQ Capital,Molten Ventures | View deal → |
| 2024-01-24 | Series A | €13M | Molten Ventures | View deal → |
